Mr. Strangis entered the Radionuclide Production Industry in the early 1990's at the Atomic Energy Commission of Argentina. He has served in positions of progressive responsibility at government and private cyclotron facilities. 

During his career, Mr. Strangis participated in many cyclotron facility projects and acquired high expertise in cyclotron engineering, target design, synthesis of radiopharmaceuticals, radiopharmacy facility startup and operations, quality assurance, quality controls, radiation safety and regulatory submissions. 

 In 2011, Mr. Strangis led Houston Cyclotron Partners L.P. dba Cyclotope through the compliance process issued by the Food and Drug Administration (FDA) for Positron Emission Tomography (P.E.T.) radiopharmaceuticals with submission deadline on June 2012. Under this new regulation, Houston Cyclotron Partners L.P. was the first company in the US to get FDA approval for all three main PET diagnostics products: Fludeoxyglucose F-18, Sodium Fluoride F-18, and Ammonia N-13. Furthermore, Mr. Strangis succesfully led the company on projects for radiopharmaceutical drugs validation with submission of various Chemical Manufacturing and Controls (CMCs) supplements and Drug Manufacturing Files (DMFs).

 In 2016, Mr. Strangis founded Stracotek, where he currently serves as president. He is currently focusing on development of high-performance cyclotron targets for production of P.E.T. radioisotopes.

​